Skip to content

Comparative outcome of triamcinolone acetonide injection between 10 mg and 20 mg in de Quervain Tenosynovitis : A randomized controlled trial

Comparative outcome of triamcinolone acetonide injection between 10 mg and 20 mg in de Quervain Tenosynovitis : A randomized controlled trial

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240429004
Enrollment
100
Registered
2024-04-29
Start date
2023-05-27
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triamcinolone acetonide injection in de Quervain Tenosynovitis de Quervain Tenosynovitis, Triamcinolone acetonide injection, TA injection

Interventions

1.The 10 mg triamcinolone acetonide medication prepared by mixing 0.5 ml of 1% Xylocaine without adrenaline with 1 ml of 10 mg/ml triamcinolone acetonide 2. Before an injection, the skin and subcu
Active Comparator Drug,Active Comparator Drug
10 mg of triamcinolone acetonide group, 20 mg of triamcinolone acetonide group

Sponsors

Mahavajiralongkorn Phramongkutklao Hospital Foundation
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patient older than 20 years of age who have diagnosed with de Quervain tenosynovitis 2.Patient who have diagnosed with de Quervain tenosynovitis who have not previously been treated with steroid injections

Exclusion criteria

Exclusion criteria: 1. Patients who had underlying inflammatory joint diseases such as rheumatoid arthritis, gouty arthritis or autoimmune disease 2. 1st CMC joint arthritis and STT joint arthritis 3. Injury to the involved wrist 4. Who had history of wrist fracture 5. Previous surgery at wrist 6. Abnormal sensation of hand 7. History of an allergy to triamcinolone acetonide or lidocaine 8.Patients who do not have a communication device that can use face-to-face calling and cannot follow up on treatment at outpatient department orthopedic division Phramongkutklao Hospital

Design outcomes

Primary

MeasureTime frame
Pain at 3 week, 6 weeks, 3 months, 6 months after end of the intervention use numerical rating scale between 0 to 10 for describe pain on the radial side of the wrist,Tenderness at 3 week, 6 weeks, 3 months, 6 months after end of the intervention palpate at the first dorsal compartment,Finkelstein test at 3 week, 6 weeks, 3 months, 6 months after end of the intervention bend the thumb across the palm of hand and bend the fingers down over the thumb. then bend the wrist toward the little finger

Secondary

MeasureTime frame
Complication: skin atrophy at 3 week, 6 weeks, 3 months, 6 months after end of the intervention skin at injection area atrophy,Complication: hypopigmentation at 3 week, 6 weeks, 3 months, 6 months after end of the intervention skin at injection area lose pigmentation ,Complication: radial nerve injury at 3 week, 6 weeks, 3 months, 6 months after end of the intervention abnormal sensations in the back and thumb side of the hand, or in the thumb, 2nd, and 3rd fingers,Complication: tendon rupture at 3 week, 6 weeks, 3 months, 6 months after end of the intervention can not extend or abduction of the thumb

Countries

Thailand

Contacts

Public ContactPawinee Theekakul

Phramongkutklao College of Medicine; Royal Thai Army Nursing College

stamp.theekakul@gmail.com0896285867

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026